Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Hepatology International
Published in: Hepatology International 4/2022

Open Access 29-06-2022 | Hepatitis B | Review Article

SARS-CoV-2 infection and liver involvement

Authors: Mingjia Luo, Maria Pilar Ballester, Ugo Soffientini, Rajiv Jalan, Gautam Mehta

Published in: Hepatology International | Issue 4/2022

Login to get access

Abstract

The COVID-19 pandemic is the largest public health challenge in living memory. Patients with underlying liver disease have been disproportionately affected, experiencing high morbidity and mortality. In addition, elevated liver enzymes appear to be a risk factor for disease progression, even in the absence of underlying liver disease. Nevertheless, the mechanism of liver injury in SARS-CoV-2 infection remains largely unknown. This review aims to provide an overview of the mechanisms by which SARS-CoV-2 induces liver injury, and the impact of COVID-19 on cirrhosis, alcohol-related liver disease, autoimmune liver disease, non-alcoholic fatty liver disease, hepatitis B and C virus infection, liver-transplant recipients and patients with hepatocellular carcinoma. Finally, emerging data on vaccination in liver diseases is discussed, to help inform public health policy.
Literature
1.
2.
Marjot T, Webb GJ, Barritt AS 4th, et al. COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol. 2021;18(5):348–364PubMedPubMedCentralCrossRef
3.
Zhao B, Ni C, Gao R, et al. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. Protein Cell. 2020;11(10):771–775PubMedPubMedCentralCrossRef
4.
Yang L, Han Y, Nilsson-Payant BE, et al. A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids. Cell Stem Cell. 2020;27(1):125-136.e7PubMedPubMedCentralCrossRef
5.
Faruqui S, Okoli FC, Olsen SK, et al. Cholangiopathy after severe COVID-19: clinical features and prognostic implications. Am J Gastroenterol. 2021;116(7):1414–1425PubMedCrossRef
6.
Chu H, Chan JF, Yuen TT, et al. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. Lancet Microbe. 2020;1(1):e14–e23PubMedPubMedCentralCrossRef
7.
Wang Y, Liu S, Liu H, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol. 2020;73(4):807–816PubMedPubMedCentralCrossRef
8.
9.
Meijnikman AS, Bruin S, Groen AK, et al. Increased expression of key SARS-CoV-2 entry points in multiple tissues in individuals with NAFLD. J Hepatol. 2021;74(3):748–749PubMedCrossRef
10.
Paizis G, Tikellis C, Cooper ME, et al. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut. 2005;54(12):1790–6PubMedPubMedCentralCrossRef
11.
Warner FJ, Rajapaksha H, Shackel N, et al. ACE2: from protection of liver disease to propagation of COVID-19. Clin Sci (Lond). 2020;134(23):3137–3158CrossRef
12.
McCarron S, Bathon B, Conlon DM, et al. Functional characterization of organoids derived from irreversibly damaged liver of patients with NASH. Hepatology. 2021;74(4):1825–1844PubMedCrossRef
13.
Clark R, Waters B, Stanfill AG. Elevated liver function tests in COVID-19: causes, clinical evidence, and potential treatments. Nurse Pract. 2021;46(1):21–26PubMedCrossRef
14.
Da BL, Kushner T, El Halabi M, et al. Liver injury in hospitalized patients with COVID-19 correlates with hyper inflammatory response and elevated IL-6. Hepatol Commun. 2020;5(2):177–88PubMedPubMedCentralCrossRef
15.
16.
Bzeizi K, Abdulla M, Mohammed N, et al. Effect of COVID-19 on liver abnormalities: a systematic review and meta-analysis. Sci Rep.
17.
Papic N, Pangercic A, Vargovic M, et al. Liver involvement during influenza infection: perspective on the 2009 influenza pandemic. Influenza Other Respir Viruses. 2012;6(3):e2-5PubMedCrossRef
18.
Shafran N, Issachar A, Shochat T, et al. Abnormal liver tests in patients with SARS-CoV-2 or influenza—prognostic similarities and temporal disparities. JHEP Rep. 2021;3(3):100258PubMedPubMedCentralCrossRef
19.
Duchini A, Viernes ME, Nyberg LM, et al. Hepatic decompensation in patients with cirrhosis during infection with influenza A. Arch Intern Med. 2000;160(1):113–5PubMedCrossRef
20.
Bal CK, Bhatia V, Kumar S, et al. Influenza A/H1/N1/09 infection in patients with cirrhosis has a poor outcome: a case series. Indian J Gastroenterol. 2014;33(2):178–82PubMedCrossRef
21.
Marjot T, Moon AM, Cook JA, et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. J Hepatol. 2021;74(3):567–577PubMedCrossRef
22.
Singh S, Khan A. Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the united states: a multicenter research network study. Gastroenterology. 2020;159(2):768-771.e3PubMedCrossRef
23.
Ioannou GN, Liang PS, Locke E, et al. Cirrhosis and severe acute respiratory syndrome coronavirus 2 infection in US veterans: risk of infection, hospitalization, ventilation, and mortality. Hepatology. 2021;74(1):322–335PubMedCrossRef
24.
Mohammed A, Paranji N, Chen PH, et al. COVID-19 in chronic liver disease and liver transplantation: a clinical review. J Clin Gastroenterol. 2021;55(3):187–194PubMedCrossRef
25.
Sarin SK, Choudhury A, Lau GK, et al. Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). Hepatol Int. 2020;14(5):690–700PubMedCrossRef
26.
Macdonald S, Andreola F, Bachtiger P, et al. Cell death markers in patients with cirrhosis and acute decompensation. Hepatology. 2018;67(3):989–1002PubMedCrossRef
27.
28.
29.
Soffientini U, Beaton N, Baweja S, et al. The lipopolysaccharide-sensing caspase(s)-4/11 are activated in cirrhosis and are causally associated with progression to multi-organ injury. Front Cell Dev Biol. 2021;9:668459PubMedPubMedCentral
30.
Pan P, Shen M, Yu Z, et al. Author Correction: SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation. Nat Commun. 2021;12(1):5306PubMedPubMedCentralCrossRef
31.
Junqueira C, Crespo Ã, Ranjbar S, et al. SARS-CoV-2 infects blood monocytes to activate NLRP3 and AIM2 inflammasomes, pyroptosis and cytokine release. Res Sq [Preprint] 2021;rs.3.rs-153628
32.
Kim D, Adeniji N, Latt N, et al. Predictors of outcomes of COVID-19 in patients with chronic liver disease: US multi-center study. Clin Gastroenterol Hepatol. 2021;19(7):1469-1479.e19PubMedCrossRef
33.
34.
Yang Z, Liu J, Zhou Y, et al. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect. 2020;81(1):e13–e20PubMedPubMedCentralCrossRef
35.
Di Giorgio A, Nicastro E, Speziani C, et al. Health status of patients with autoimmune liver disease during SARS-CoV-2 outbreak in northern Italy. J Hepatol. 2020;73(3):702–705PubMedPubMedCentralCrossRef
36.
Verhelst X, Somers N, Geerts A, et al. Health status of patients with autoimmune hepatitis is not affected by the SARS-CoV-2 outbreak in Flanders, Belgium. J Hepatol. 2021;74(1):240–241PubMedCrossRef
37.
Efe C, Dhanasekaran R, Lammert C, et al. Outcome of COVID-19 in patients with autoimmune hepatitis: an international multicenter study. Hepatology. 2021;73(6):2099–2109PubMedCrossRef
38.
39.
Zheng KI, Gao F, Wang XB, et al. Letter to the EditOR Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism. 2020;108:154244PubMedPubMedCentralCrossRef
40.
Targher G, Mantovani A, Byrne CD, et al. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut. 2020;69(8):1545–1547PubMedCrossRef
41.
Liu J, Wang T, Cai Q, et al. Longitudinal changes of liver function and hepatitis B reactivation in COVID-19 patients with pre-existing chronic hepatitis B virus infection. Hepatol Res. 2020;50(11):1211–1221PubMedPubMedCentralCrossRef
42.
Chen X, Jiang Q, Ma Z, et al. Clinical characteristics of hospitalized patients with SARS-CoV-2 and hepatitis B virus co-infection. Virol Sin. 2020;35(6):842–845PubMedPubMedCentralCrossRef
43.
Rodríguez-Tajes S, Miralpeix A, Costa J, et al. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy. J Viral Hepat. 2021;28(1):89–94PubMedCrossRef
44.
Choe JW, Jung YK, Yim HJ, et al. Clinical effect of hepatitis B virus on COVID-19 infected patients: a nationwide population-based study using the health insurance review and assessment service database. J Korean Med Sci. 2022;37(4):e29PubMedPubMedCentralCrossRef
45.
Kang SH, Cho DH, Choi J, et al. Association between chronic hepatitis B infection and COVID-19 outcomes: a Korean nationwide cohort study. PLoS One. 2021;16(10):e0258229PubMedPubMedCentralCrossRef
46.
Ronderos D, Omar AMS, Abbas H, et al. Chronic hepatitis-C infection in COVID-19 patients is associated with in-hospital mortality. World J Clin Cases. 2021;9(29):8749–8762PubMedPubMedCentralCrossRef
47.
Cerbu B, Pantea S, Bratosin F, et al. Liver impairment and hematological changes in patients with chronic hepatitis C and COVID-19: a retrospective study after one year of pandemic. Med (Kaunas). 2021;57(6):597
48.
Butt AA, Yan P, Chotani RA, et al. Mortality is not increased in SARS-CoV-2 infected persons with hepatitis C virus infection. Liver Int. 2021;41(8):1824–1831PubMedPubMedCentralCrossRef
49.
Lens S, Miquel M, Mateos-Muñoz B, et al. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. J Hepatol. 2021;74(1):148–155
50.
Colmenero J, Rodríguez-Perálvarez M, Salcedo M, et al. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. J Hepatol. 2021;74(1):148–155PubMedCrossRef
51.
Webb GJ, Marjot T, Cook JA, et al. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. Lancet Gastroenterol Hepatol. 2020;5(11):1008–1016PubMedPubMedCentralCrossRef
52.
Bhoori S, Rossi RE, Citterio D, et al. COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy. Lancet Gastroenterol Hepatol. 2020;5(6):532–533PubMedPubMedCentralCrossRef
53.
Webb GJ, Moon AM, Barnes E, et al. Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients. J Hepatol. 2021;75(1):226–228PubMedPubMedCentralCrossRef
54.
Rabiee A, Sadowski B, Adeniji N, et al. Liver injury in liver transplant recipients with coronavirus disease 2019 (COVID-19): US multicenter experience. Hepatology. 2020;72(6):1900–1911PubMedCrossRef
55.
John BV, Deng Y, Scheinberg A, et al. Association of BNT162b2 mRNA and mRNA-1273 vaccines With COVID-19 infection and hospitalization among patients with cirrhosis. JAMA Intern Med. 2021;181(10):1306–1314PubMedCrossRef
56.
57.
Wang J, Hou Z, Liu J, et al. Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): a multicenter study. J Hepatol. 2021;75(2):439–441PubMedPubMedCentralCrossRef
58.
Thuluvath PJ, Robarts P, Chauhan M. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases. J Hepatol. 2021;75(6):1434–1439PubMedPubMedCentralCrossRef
59.
Iavarone M, Tosetti G, Facchetti F, et al. Delayed and suboptimal response to two doses of SARS-CoV-2 messenger RNA vaccine in European patients with compensated and decompensated cirrhosis of difference aetiologies. Hepatology. 2021;74(6):1391A
60.
Rabinowich L, Grupper A, Baruch R, et al. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. J Hepatol. 2021;75(2):435–438PubMedPubMedCentralCrossRef
Metadata
Title
SARS-CoV-2 infection and liver involvement
Authors
Mingjia Luo
Maria Pilar Ballester
Ugo Soffientini
Rajiv Jalan
Gautam Mehta
Publication date
29-06-2022
Publisher
Springer India
Published in
Hepatology International / Issue 4/2022
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-022-10364-1

Other articles of this Issue 4/2022

Hepatology International 4/2022 Go to the issue

Original Article

Associations between intake of starchy and non-starchy vegetables and risk of hepatic steatosis and fibrosis

Original Article

Machine learning models in the prediction of 1-year mortality in patients with advanced hepatocellular cancer on immunotherapy: a proof-of-concept study

Original Article

The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study

Original Article

Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies

Original Article

Complications of congenital portosystemic shunts: liver tumors are affected by shunt severity, but pulmonary and neurocognitive associations are not

Original Article

A novel epithelial–mesenchymal transition gene signature for the immune status and prognosis of hepatocellular carcinoma

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits